Palvella 将在 PeDRA 年会展示 QTORIN™ 雷帕霉素 SELVA/TOIVA 儿科亚组分析，主体为既往数据的二次分析

Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding
Phase 2 TOIVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and Reductions in Lesion Bleeding in Previously Treated Children with Cutaneous Venous Malformations
QTORIN™ Rapamycin Has the Potential to Become the First FDA-Approved Therapy for Both Microcystic Lymphatic Malformations and Cutaneous Venous Malformations, Two Serious, Rare Diseases with No FDA-Approved Therapies
WAYNE, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will present two posters featuring previously reported results from its Phase 3 SELVA and Phase 2 TOIVA clinical studies of QTORIN™ rapamycin, along with additional new pediatric analyses, at the Pediatric Dermatology Research Alliance (PeDRA) Annual Conference, taking place October 15–17, 2026, in Alexandria, Virginia. Copies of the posters are available
here
in the “Publications & Presentations” section of Palvella’s website.
“Microcystic lymphatic malformations and cutaneous venous malformations are serious, rare genetic diseases that can cause bleeding and chronically debilitating complications beginning in childhood and continuing throughout life,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics. “These encouraging pediatric findings highlight the potential of QTORIN™ rapamycin to address disease manifestations early in life, before these conditions progress and cause further complications. We continue to advance QTORIN™ rapamycin with a sense of urgency for both of these serious, rare diseases, with the objective of delivering a first-in-disease FDA-approved therapy that meaningfully improves the lives of affected children and adults.”
Details of the Poster Presentations
Title:
Phase 3 SELVA: Investigational QTORIN™ Sirolimus Topical Gel 3.9% Improved Disease Severity and Key Lesion Characteristics in Children With Microcystic Lymphatic Malformations
Poster Number:
036
Session:
Poster reception
Date/Time:
October 15, 2026, 5:00–7:00 p.m.
Location:
Poster Hall
Presenter:
Kristen Kahle, Ph.D.
Title:
Phase 2 TOIVA: Overall Disease Severity and Lesion Bleeding Were Reduced in Pediatric Participants With Cutaneous Venous Malformations Treated With Investigational QTORIN™ Sirolimus Topical Gel 3.9%
Poster Number:
035
Session:
Poster reception
Date/Time:
October 15, 2026, 5:00–7:00 p.m.
Location:
Poster Hall
Presenter:
Kristen Kahle, Ph.D.
In addition to the scientific presentations, Palvella will feature its BEYOND mLM disease awareness initiative at the PeDRA Annual Conference through a dedicated booth focused on education and awareness of microcystic lymphatic malformations. BEYOND mLM and its educational website,
BEYONDmLM.com
, were developed in collaboration with PeDRA, the Consortium of iNvestigators of Vascular AnomalieS (CaNVAS), The Lymphatic Malformations Alliance (formerly known as Lymphangiomatosis & Gorham’s Disease Alliance), the Lymphatic Education & Research Network (LE&RN), and VAccess.org.
About Palvella Therapeutics
Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients living with serious, rare skin diseases and vascular anomalies for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular anomalies, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit
www.palvellatx.com
or follow Palvella on
LinkedIn
or
X
(formerly known as Twitter).
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella, as well as assumptions made by, and information currently available to, the management of Palvella. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the expected timing of the presentation of data from clinical trials, Palvella’s clinical development plans and related anticipated development milestones and anticipated timing of regulatory submissions, Palvella’s plans with respect to the timing of, and anticipated FDA review process for, the NDA for QTORIN™ rapamycin, Palvella’s plans to pursue Breakthrough Therapy Designation, Palvella’s plans to meet with regulatory authorities, Palvella’s expectations regarding the benefits of orphan drug designation and potential benefit of orphan drug exclusivity for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, Palvella’s cash, financial resources and expected runway, Palvella’s expectations regarding its programs, including QTORIN™ rapamycin and QTORIN™ pitavastatin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to make regulatory submissions on anticipated timelines; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORIN™ rapamycin and QTORIN™ pitavastatin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; Palvella’s limited experience in commercial manufacturing; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella to protect its intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations; and the risks and uncertainties described in the filings made by Palvella with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at
www.sec.gov
. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Palvella may face. Except as required by applicable law, Palvella does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO
Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Vice President, Investor Relations and Corporate Affairs
Palvella Therapeutics
marcy.nanus@palvellatx.com